Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach

Table 1 Outcomes in four consensus molecular subtype profiles

Ref.	n	Outcomes	CMS1, mean (95%CI)	CMS2, mean (95%CI)	CMS3, mean (95%CI)	CMS4, mean (95%CI)
Stages I-IV
Purcell et al[39], 2019	257	5-yr OS (%)	63.7 (51.1-79.4)	64.4 (56.6-73.4)	52.8 (37.1-75.1)	42.8 (23.8-76.8)
		5-yr PFS (%)	61.2 (48.8-76.8)	59.8 (51.8-68.9)	52.7 (47.5-74.0)	38.8 (21.0-71.9)
Guinney et al[8], 2015	2129	5-yr OS (%)	74 (70-75)	77 (74-80)	75 (70-80)	62 (58-66)
		5-yr DFS (%)	75 (70-80)	73 (70-77)	73 (68-80)	60 (55-65)
Stage II
Shinto et al[36], 2020	232	5-yr DFS (%)	100	85.5	92.3	73
Stage IV
Borelli et al[43], 2021	426	OS (mo)	13.7 (6.1-27.9)	27.0 (23.9-30.1)	18.3 (16.1-24.0)	26.2 (21.4-29.9)
		PFS (mo)	5.4 (3.8-9.9)	12.9 (11.0-14.3)	8.3 (7.4-10.1)	10.7 (9.8-13.1)
Stintzing et al[20], 2019	438	OS (mo)	15.9 (11.0-20.8)	29.0 (26.7-31.4)	18.6 (15.4-21.7)	24.8 (22.6-27.1)
		PFS (mo)	8.2 (6.7-9.6)	11.7 (10.8-12.6)	8.5 (6.8-10.3)	9.6 (8.6-10.6)
Lenz et al[16], 2019	581	OS (mo)	15.0 (11.7-22.4)	40.3 (36.1-43.1)	24.3 (16.4-29.0)	31.4 (26.3-36.9)
		PFS (mo)	7.1 (5.7-8.6)	13.4 (12.8-15.4)	8.7 (7.2-9.8)	11.0 (9.7-12.0)
Mooi et al[41], 2018	237	OS (mo)	8.8 (6.5-16.0)	24.2 (19.1-27.4)	17.6 (11.3-24.6)	21.4 (15.8-23.1)
		PFS (mo)	No statistical differences in this cohort
Okita et al[42], 2018	193	OS (mo)	21.4 (13.3-35.5)	48.1 (34.8-65.6)	38.7 (30.6-45.6)	44.0 (33.0-50.5)

OS: Overall survival; DFS: Disease-free survival; PFS: Progression-free survival.